US Bancorp’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

US Bancorp’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,000	Closed	-$5K	–	4343
2022 Q1	$5K	Hold	3,000	–	–	﹤0.01%	3647
2021 Q4	$7K	Buy	3,000 +2,000	+200%	+$8.14K	﹤0.01%	3566
2021 Q3	$5K	Hold	1,000	–	–	﹤0.01%	3681
2021 Q2	$7K	Hold	1,000	–	–	﹤0.01%	3543
2021 Q1	$8K	Sell	1,000 -1,000	-50%	-$10.9K	﹤0.01%	3394
2020 Q4	$18K	Hold	2,000	–	–	﹤0.01%	2972
2020 Q3	$22K	Buy	2,000 +1,250	+167%	+$8.66K	﹤0.01%	2785
2020 Q2	$6K	Hold	750	–	–	﹤0.01%	3283
2020 Q1	$5K	Buy	750 +200	+36%	+$1.3K	﹤0.01%	3289
2019 Q4	$3K	Hold	550	–	–	﹤0.01%	3437
2019 Q3	$4K	Buy	+550	New	+$4.78K	﹤0.01%	3314

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

US Bancorp's KLDO Position: Q2 2022 in Review

US Bancorp sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 3,000 shares — an estimated $5K sold.

US Bancorp first reported a position in KLDO in Q3 2019 and held it in 11 quarters. The position peaked at $22K in Q3 2020. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

US Bancorp reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
US Bancorp sold 3,000 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $5K.
US Bancorp first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
US Bancorp's Kaleido Biosciences, Inc. Common Stock position peaked at $22K in Q3 2020.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on US Bancorp's 13F filing for Q2 2022, filed 1 Aug 2022.